Early Intervention in Allergic Patients

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

As many as 250 million people suffer from allergic rhinitis in China, which has a large population, early use of drugs may help better control the symptoms.This study aimed to investigate the effects of early interventional treatment with the leukotriene receptor antagonist (LTRA) montelukast on seasonal allergic rhinitis.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00656058` - Montelukast to Treat Bronchiolitis Obliterans	Phase 2
	Active, not recruiting	`NCT05143502` - Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.	Phase 1/Phase 2

NCT number	NCT05040828
Study type	Interventional
Source	Beijing Tongren Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	July 1, 2020
Completion date	November 10, 2020

Early Intervention in Allergic Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms